TLDR: India’s digital health startups are at the forefront of a revolution in diabetes management, integrating artificial intelligence (AI) and wearable technology to offer personalized, proactive, and data-driven care. These innovations aim to empower patients with real-time insights, streamline treatment, and shift healthcare from reactive to continuous monitoring.
India’s burgeoning digital health sector is making significant strides in combating the rising tide of diabetes, with startups increasingly harnessing the power of artificial intelligence (AI) and wearable devices. This technological convergence is transforming how diabetes is managed, moving towards more personalized, proactive, and efficient care models.
Companies like Sugar.fit are leading this charge, offering comprehensive diabetes care programs that integrate wearable Continuous Glucose Monitors (CGMs), real-time coaching, and tailored interventions. Sugar.fit, which has successfully raised $16 million, including a $5 million round from B Capital, provides a full-stack approach encompassing lifestyle tracking, medication adherence, and diet support within a unified consumer experience. This positions them as pioneers in condition-specific platforms focused on tangible health outcomes rather than just engagement.
Another notable player, Eka Care, offers a digital therapeutic application designed for managing various conditions, including diabetes. Their platform enables users to monitor blood sugar levels and receive individualized recommendations on diet, exercise, sleep, and stress based on their data. Eka Care has secured $19.5 million in funding, highlighting investor confidence in AI-driven health solutions.
The broader impact of these technologies is profound. As Dr. Richa Chaturvedi emphasizes, CGMs provide real-time glucose readings, significantly reducing the need for frequent fingerstick tests and helping patients avoid dangerous fluctuations in blood sugar. Similarly, insulin pumps simplify diabetes management by minimizing the need for multiple daily injections. The integration of these technologies, particularly closed-loop systems that combine CGMs with insulin pumps to automatically adjust insulin delivery, is akin to creating an ‘artificial pancreas.’ This innovation not only enhances glycemic control but also substantially lowers the risk of severe complications like diabetic ketoacidosis.
Dr. Varsha Kachroo further notes that digital health tools, AI, and wearable devices are fundamentally reshaping the landscape for both patients and clinicians. Gerald Jaideep, CEO of Medvarsity Online, points out a crucial shift in healthcare: from periodic check-ups to continuous, data-driven care management. Telemedicine and mobile health applications are also expanding access to care and improving patient education, allowing for remote monitoring and seamless communication between patients and healthcare providers. Patients can readily share their glucose data through these apps, facilitating timely adjustments to their treatment plans without requiring in-person clinic visits.
Other innovative startups contributing to this ecosystem include Ultrahuman, which focuses on metabolic health tracking using glucose biomarkers and performance coaches, and BeatO, known for its smartphone-enabled glucometer and diabetes management app that delivers personalized insights. Even established players like Abbott are contributing with advanced CGM systems that offer real-time glucose monitoring and associated mobile applications for data tracking and sharing.
Also Read:
- Artificial Intelligence Revolutionizes Clinical Trials in India
- Indian AI Startups Witness Significant Funding Surge, Reaching $665 Million in First Seven Months of 2025
This wave of innovation underscores India’s commitment to leveraging advanced technology to address chronic diseases, promising a future where diabetes management is more accessible, personalized, and effective.
